Korean J Head Neck Oncol Search


Korean Journal of Head & Neck Oncology 1999;15(2):149-155.
Published online November 30, 1999.
Clinical Features and Prognostic Factors in 41 Patients of Primary Nasal/Nasopharyngeal Non-Hodgkin's Lymphoma: Prognostic Significance of Immunophenotype
Soon Seo Park;Cheol won Suh;Jong Beom Park;Ji Woon Park;Soo Duk Lim;Joo ryung Huh;Soon Yuhl Nam;Sang Yoon Kim;Hye sook Chang;Tae Won Kim;Je Hwan Lee;Sung Bae Kim;Sang We Kim;Kyoo Hyung Lee;Jung Shin Lee;Woo Kun Kim;Sang Hee Kim
비/비인강 비호즈킨 림프종의 임상양상과 예후 인자 면역 표현형의 임상적 의의
Objectives: To study the clinical features of the primary nasal/nasopharyngeal non-Hodgkin's lymphomas and to evaluate the implication of immunophenotyping as a prognostic factor. Patients and Methods: From January 1990 to December 1997,41 patients(median age, 41 years) of primary nasal/nasopharyngeal non-Hodgkin's lymphoma were studied. The clinical records and paraffin-embedded tissue blocks were reviewed retrospectively. The histologic features, immunophenotypic findings(pan-T, pan-B, CD3, CD56) and Epstein-Barr virus in situ hybridizatios were examined. The prognostic factors for clinical outcome were evaluated in these patients. According to Ann-Arbor system, there were 30 patiets(73%) with stage IE, 4(10%) with stage IIE, 3(7%) with stage IIIE, 4(10%) with stage IVE lymphoma. Among the patients with stage IE/IIE, 4 patients received local radiation alone, 4 received chemotherapy alone, 25 received combination chemotherapy and radiotherapy and 1 refused treatment. The patients with stage IIIE/IVE were given combination chemotherapy and radiotherapy.
Immunophenotyping were performed in 40 patients and staining results were as follows: 3(7%) patients with B cell, 17(42%) with T cell, 18(44%) with NK/T cell(CD56 positive), and two patients with unclassifiable result. Epstein-Barr(EB) virus in situ hybridization were performed in 28 patients and 23(82%) patients had positive EBV-encoded RNAs(EBERs). 21(55%) patients achieved a complete remission. There was no difference in complete remission between radiation alone and combination therapy. With median follow-up of 30 months, 5-years disease free survival of complete responders was 60% and 5-years overall survival rate was 36%. Multivariate analysis showed that better overall survival was related with absence of B symptoms, ECOG performance ≤1 and non-NK cells.
Most of all cases were positive for EBER. Since NK/T phenotype carried the worst prognosis, analysis for CD56 expression should be done. Further prospective studies were warranted to evaluate the role of chemotherapy in stage IE/IIE.
Share :
Facebook Twitter Linked In Google+ Line it
METRICS Graph View
  • 307 View
  • 2 Download
Related articles in Korean J Head Neck Oncol


Browse all articles >

Editorial Office
327, Sosa-ro, Bucheon-si, Gyeonggi-do 14647, Korea
Tel: +82-10-9810-7671    Fax: +82-504-223-7671    E-mail: kshno@hanmail.net                

Copyright © 2022 by Korean Society for Head & Neck Oncology.

Developed in M2PI

Close layer
prev next